• Profile

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): A multicenter, prospective, case-control study

The Lancet: Gastroenterology & Hepatology Feb 08, 2022

In view of the uncertainty concerning the effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination, researchers herein examined if patients with IBD on commonly used immunosuppressive drugs show altered COVID-19 vaccine-induced antibody responses.

  • In this multicenter, prospective, case-control study (VIP), a total of 483 participants were recruited, including patients with IBD being treated with thiopurines (n = 78), infliximab (n = 63), a thiopurine plus infliximab (n = 72), ustekinumab (n = 57), vedolizumab (n = 62), or tofacitinib (n = 30), and 121 healthy controls.

  • The primary analysis was performed including 370 participants without evidence of previous infection.

  • The immunogenicity of COVID-19 vaccines varies among patients with IBD according to immunosuppressive drug exposure, and is attenuated in recipients of infliximab, infliximab plus thiopurines, and tofacitinib.

  • On the basis of an individual's treatment, researchers suggest personalized scheduling of third primary, or booster, doses, and prioritization of patients taking anti-tumor necrosis factor and tofacitinib.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen